DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis Article Swipe

PDF

K Li , Joshua R. Friedman , Colleen Marano , H Zhang , Feifei Yang , Brian G. Feagan , Laurent Peyrin‐Biroulet , Gert De Hertogh ·

YOU? · · 2019 · Open Access · · DOI: https://doi.org/10.1093/ecco-jcc/jjy222.105

Ustekinumab (UST) is an effective therapy for moderate–severe UC; however, data regarding histological healing and the combination of histological and endoscopic healing (also described as endoscopic improvement in the appearance of the mucosa) are unknown. We evaluated the effects of UST on histological and endoscopic activity in the UNIFI Ph3 induction study of UST in moderate–severe UC(n = 961). Two colonic biopsies were collected from distal colon at screening and induction Wk8. Subjects not in response to placebo (PBO) at Wk8 received UST 6 mg/kg IV, and those not in response to UST IV received UST 90 mg SC; biopsies were obtained at Wk16. Endoscopic healing (EH; also described a endoscopic improvement in the appearance of mucosa) was defined as a Mayo endoscopy score <1; histological healing (HH) comprised the following Geboes score-based criteria: absence of erosion or ulceration, absence of crypt destruction, and <5% of crypts with epithelial neutrophil infiltration. To encompass both macro- and microscopic scales, histo-endoscopic mucosal healing (HEMH) was defined as achieving both EH and HH. At Wk8, EH was achieved in 26.6% and 13.8% of subjects treated with UST (combined 130 mg and 6 mg/kg IV doses)and PBO, respectively (adjusted tx difference, 12.8%; 95% CI, 7.9–17.8; p < 0.001). HH was achieved in 36.8% and 21.9% of UST and PBO-treated subjects, respectively (adjusted tx difference, 15.0%; 95% CI, 9.0–21.0; p < 0.001). Histo-endoscopic mucosal (HEMH) was achieved in 19.3% and 8.9% of UST and PBO-treated subjects, respectively (adjusted tx difference, 12.5%; 95% CI, 6.2–14.8; p < 0.001). Similar rates of EH, HH, and HEMH were achieved following induction with UST 130 mg or 6 mg/kg IV. Subjects not in response to PBO or UST at Wk8 were treated with UST at that time and re-evaluated at Wk16; of these, 12.1% and 16.5% of subjects who initially received UST or PBO IV, respectively, achieved HEMH. HH at Wk8 or Wk16 (irrespective of induction tx) was significantly associated with EH and HEMH (p < 0.001) and with both absolute levels and post-tx changes in Mayo score, partial Mayo score, and Mayo symptom sub-scores for stool frequency and rectal bleeding. Table 1. Clinical outcomes for subjects with or without histological healing at Week 8 and Week 16 in the UNIFI Phase 3 induction study Among subjects with moderately–severely active UC, those receiving IV UST induction had higher rates of EH, HH, and HEMH than those receiving PBO. Approximately 10% of subjects who did not achieve clinical response 8 weeks after IV UST achieved HEMH following a second (SC) dose. HH is associated with reductions in clinical and endoscopic disease activity as well as patient-reported symptoms.

Related Topics

Concepts

Ustekinumab Ulcerative colitis Medicine Colitis Internal medicine Gastroenterology Dermatology Disease Infliximab

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1093/ecco-jcc/jjy222.105
PDF: https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf
OA Status: bronze
Cited By: 5
Related Works: 10
OpenAlex ID: https://openalex.org/W2913845025

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W2913845025

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1093/ecco-jcc/jjy222.105

Digital Object Identifier
Title: DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2019

Year of publication
Publication date: 2019-01-25

Full publication date if available
Authors: K Li, Joshua R. Friedman, Colleen Marano, H Zhang, Feifei Yang, Brian G. Feagan, Laurent Peyrin‐Biroulet, Gert De Hertogh

List of authors in order
Landing page: https://doi.org/10.1093/ecco-jcc/jjy222.105

Publisher landing page
PDF URL: https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: bronze

Open access status per OpenAlex
OA URL: https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf

Direct OA link when available
Concepts: Ustekinumab, Ulcerative colitis, Medicine, Colitis, Internal medicine, Gastroenterology, Dermatology, Disease, Infliximab

Top concepts (fields/topics) attached by OpenAlex
Cited by: 5

Total citation count in OpenAlex
Citations by year (recent): 2024: 1, 2019: 4

Per-year citation counts (last 5 years)
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W2913845025
doi	https://doi.org/10.1093/ecco-jcc/jjy222.105
ids.doi	https://doi.org/10.1093/ecco-jcc/jjy222.105
ids.mag	2913845025
ids.openalex	https://openalex.org/W2913845025
fwci	0.71050101
type	article
title	DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
biblio.issue	Supplement_1
biblio.volume	13
biblio.last_page	S073
biblio.first_page	S073
topics[0].id	https://openalex.org/T10134
topics[0].field.id	https://openalex.org/fields/13
topics[0].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[0].score	0.9988999962806702
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/1311
topics[0].subfield.display_name	Genetics
topics[0].display_name	Inflammatory Bowel Disease
topics[1].id	https://openalex.org/T13569
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9940999746322632
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2713
topics[1].subfield.display_name	Epidemiology
topics[1].display_name	Microscopic Colitis
topics[2].id	https://openalex.org/T12064
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9595000147819519
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2746
topics[2].subfield.display_name	Surgery
topics[2].display_name	Intraperitoneal and Appendiceal Malignancies
is_xpac	False
apc_list.value	3881
apc_list.currency	EUR
apc_list.value_usd	4185
apc_paid
concepts[0].id	https://openalex.org/C2778975655
concepts[0].level	4
concepts[0].score	0.9035452604293823
concepts[0].wikidata	https://www.wikidata.org/wiki/Q420305
concepts[0].display_name	Ustekinumab
concepts[1].id	https://openalex.org/C2780479503
concepts[1].level	3
concepts[1].score	0.8455452919006348
concepts[1].wikidata	https://www.wikidata.org/wiki/Q1477
concepts[1].display_name	Ulcerative colitis
concepts[2].id	https://openalex.org/C71924100
concepts[2].level	0
concepts[2].score	0.6539590954780579
concepts[2].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[2].display_name	Medicine
concepts[3].id	https://openalex.org/C2775862500
concepts[3].level	2
concepts[3].score	0.4634297788143158
concepts[3].wikidata	https://www.wikidata.org/wiki/Q2453464
concepts[3].display_name	Colitis
concepts[4].id	https://openalex.org/C126322002
concepts[4].level	1
concepts[4].score	0.40945136547088623
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[4].display_name	Internal medicine
concepts[5].id	https://openalex.org/C90924648
concepts[5].level	1
concepts[5].score	0.3833279013633728
concepts[5].wikidata	https://www.wikidata.org/wiki/Q120569
concepts[5].display_name	Gastroenterology
concepts[6].id	https://openalex.org/C16005928
concepts[6].level	1
concepts[6].score	0.34436166286468506
concepts[6].wikidata	https://www.wikidata.org/wiki/Q171171
concepts[6].display_name	Dermatology
concepts[7].id	https://openalex.org/C2779134260
concepts[7].level	2
concepts[7].score	0.19113695621490479
concepts[7].wikidata	https://www.wikidata.org/wiki/Q12136
concepts[7].display_name	Disease
concepts[8].id	https://openalex.org/C2777138892
concepts[8].level	3
concepts[8].score	0.0
concepts[8].wikidata	https://www.wikidata.org/wiki/Q415264
concepts[8].display_name	Infliximab
keywords[0].id	https://openalex.org/keywords/ustekinumab
keywords[0].score	0.9035452604293823
keywords[0].display_name	Ustekinumab
keywords[1].id	https://openalex.org/keywords/ulcerative-colitis
keywords[1].score	0.8455452919006348
keywords[1].display_name	Ulcerative colitis
keywords[2].id	https://openalex.org/keywords/medicine
keywords[2].score	0.6539590954780579
keywords[2].display_name	Medicine
keywords[3].id	https://openalex.org/keywords/colitis
keywords[3].score	0.4634297788143158
keywords[3].display_name	Colitis
keywords[4].id	https://openalex.org/keywords/internal-medicine
keywords[4].score	0.40945136547088623
keywords[4].display_name	Internal medicine
keywords[5].id	https://openalex.org/keywords/gastroenterology
keywords[5].score	0.3833279013633728
keywords[5].display_name	Gastroenterology
keywords[6].id	https://openalex.org/keywords/dermatology
keywords[6].score	0.34436166286468506
keywords[6].display_name	Dermatology
keywords[7].id	https://openalex.org/keywords/disease
keywords[7].score	0.19113695621490479
keywords[7].display_name	Disease
language	en
locations[0].id	doi:10.1093/ecco-jcc/jjy222.105
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S2735960814
locations[0].source.issn	1873-9946, 1876-4479
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	1873-9946
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Journal of Crohn s and Colitis
locations[0].source.host_organization	https://openalex.org/P4310311648
locations[0].source.host_organization_name	Oxford University Press
locations[0].source.host_organization_lineage	https://openalex.org/P4310311648
locations[0].license
locations[0].pdf_url	https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Journal of Crohn's and Colitis
locations[0].landing_page_url	https://doi.org/10.1093/ecco-jcc/jjy222.105
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5018278447
authorships[0].author.orcid
authorships[0].author.display_name	K Li
authorships[0].countries	US
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210151386
authorships[0].affiliations[0].raw_affiliation_string	Janssen Research and Development, LLC, Spring House, USA
authorships[0].institutions[0].id	https://openalex.org/I4210151386
authorships[0].institutions[0].ror	https://ror.org/05af73403
authorships[0].institutions[0].type	company
authorships[0].institutions[0].lineage	https://openalex.org/I1330063522, https://openalex.org/I4210151386
authorships[0].institutions[0].country_code	US
authorships[0].institutions[0].display_name	Janssen (United States)
authorships[0].author_position	first
authorships[0].raw_author_name	K Li
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Janssen Research and Development, LLC, Spring House, USA
authorships[1].author.id	https://openalex.org/A5011427142
authorships[1].author.orcid	https://orcid.org/0000-0001-9382-8429
authorships[1].author.display_name	Joshua R. Friedman
authorships[1].countries	US
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210151386
authorships[1].affiliations[0].raw_affiliation_string	Janssen Research and Development, LLC, Spring House, USA
authorships[1].institutions[0].id	https://openalex.org/I4210151386
authorships[1].institutions[0].ror	https://ror.org/05af73403
authorships[1].institutions[0].type	company
authorships[1].institutions[0].lineage	https://openalex.org/I1330063522, https://openalex.org/I4210151386
authorships[1].institutions[0].country_code	US
authorships[1].institutions[0].display_name	Janssen (United States)
authorships[1].author_position	middle
authorships[1].raw_author_name	J R Friedman
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Janssen Research and Development, LLC, Spring House, USA
authorships[2].author.id	https://openalex.org/A5052046238
authorships[2].author.orcid	https://orcid.org/0000-0002-4965-5142
authorships[2].author.display_name	Colleen Marano
authorships[2].countries	US
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210151386
authorships[2].affiliations[0].raw_affiliation_string	Janssen Research and Development, LLC, Spring House, USA
authorships[2].institutions[0].id	https://openalex.org/I4210151386
authorships[2].institutions[0].ror	https://ror.org/05af73403
authorships[2].institutions[0].type	company
authorships[2].institutions[0].lineage	https://openalex.org/I1330063522, https://openalex.org/I4210151386
authorships[2].institutions[0].country_code	US
authorships[2].institutions[0].display_name	Janssen (United States)
authorships[2].author_position	middle
authorships[2].raw_author_name	C Marano
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Janssen Research and Development, LLC, Spring House, USA
authorships[3].author.id	https://openalex.org/A5035601572
authorships[3].author.orcid	https://orcid.org/0009-0007-7202-9397
authorships[3].author.display_name	H Zhang
authorships[3].countries	US
authorships[3].affiliations[0].institution_ids	https://openalex.org/I4210151386
authorships[3].affiliations[0].raw_affiliation_string	Janssen Research and Development, LLC, Spring House, USA
authorships[3].institutions[0].id	https://openalex.org/I4210151386
authorships[3].institutions[0].ror	https://ror.org/05af73403
authorships[3].institutions[0].type	company
authorships[3].institutions[0].lineage	https://openalex.org/I1330063522, https://openalex.org/I4210151386
authorships[3].institutions[0].country_code	US
authorships[3].institutions[0].display_name	Janssen (United States)
authorships[3].author_position	middle
authorships[3].raw_author_name	H Zhang
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Janssen Research and Development, LLC, Spring House, USA
authorships[4].author.id	https://openalex.org/A5031302163
authorships[4].author.orcid	https://orcid.org/0000-0001-9362-7635
authorships[4].author.display_name	Feifei Yang
authorships[4].countries	US
authorships[4].affiliations[0].institution_ids	https://openalex.org/I4210151386
authorships[4].affiliations[0].raw_affiliation_string	Janssen Research and Development, LLC, Spring House, USA
authorships[4].institutions[0].id	https://openalex.org/I4210151386
authorships[4].institutions[0].ror	https://ror.org/05af73403
authorships[4].institutions[0].type	company
authorships[4].institutions[0].lineage	https://openalex.org/I1330063522, https://openalex.org/I4210151386
authorships[4].institutions[0].country_code	US
authorships[4].institutions[0].display_name	Janssen (United States)
authorships[4].author_position	middle
authorships[4].raw_author_name	F Yang
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Janssen Research and Development, LLC, Spring House, USA
authorships[5].author.id	https://openalex.org/A5048464948
authorships[5].author.orcid	https://orcid.org/0000-0002-6914-3822
authorships[5].author.display_name	Brian G. Feagan
authorships[5].countries	CA
authorships[5].affiliations[0].institution_ids	https://openalex.org/I4210105758
authorships[5].affiliations[0].raw_affiliation_string	Robarts Research Institute, Robarts Clinical Trials, London, Canada
authorships[5].institutions[0].id	https://openalex.org/I4210105758
authorships[5].institutions[0].ror	https://ror.org/01e36dv41
authorships[5].institutions[0].type	facility
authorships[5].institutions[0].lineage	https://openalex.org/I125749732, https://openalex.org/I4210105758, https://openalex.org/I4405252475
authorships[5].institutions[0].country_code	CA
authorships[5].institutions[0].display_name	Robarts Clinical Trials
authorships[5].author_position	middle
authorships[5].raw_author_name	B G Feagan
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Robarts Research Institute, Robarts Clinical Trials, London, Canada
authorships[6].author.id	https://openalex.org/A5042884495
authorships[6].author.orcid	https://orcid.org/0000-0003-2536-6618
authorships[6].author.display_name	Laurent Peyrin‐Biroulet
authorships[6].countries	FR
authorships[6].affiliations[0].institution_ids	https://openalex.org/I90183372
authorships[6].affiliations[0].raw_affiliation_string	Nancy University Hospital, Université de Lorraine, Nancy, France
authorships[6].institutions[0].id	https://openalex.org/I90183372
authorships[6].institutions[0].ror	https://ror.org/04vfs2w97
authorships[6].institutions[0].type	education
authorships[6].institutions[0].lineage	https://openalex.org/I90183372
authorships[6].institutions[0].country_code	FR
authorships[6].institutions[0].display_name	Université de Lorraine
authorships[6].author_position	middle
authorships[6].raw_author_name	L Peyrin-Biroulet
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Nancy University Hospital, Université de Lorraine, Nancy, France
authorships[7].author.id	https://openalex.org/A5003632939
authorships[7].author.orcid	https://orcid.org/0000-0001-8494-7725
authorships[7].author.display_name	Gert De Hertogh
authorships[7].countries	BE
authorships[7].affiliations[0].institution_ids	https://openalex.org/I99464096
authorships[7].affiliations[0].raw_affiliation_string	University Hospitals KU, Leuven, Belgium
authorships[7].institutions[0].id	https://openalex.org/I99464096
authorships[7].institutions[0].ror	https://ror.org/05f950310
authorships[7].institutions[0].type	education
authorships[7].institutions[0].lineage	https://openalex.org/I99464096
authorships[7].institutions[0].country_code	BE
authorships[7].institutions[0].display_name	KU Leuven
authorships[7].author_position	last
authorships[7].raw_author_name	G De Hertogh
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	University Hospitals KU, Leuven, Belgium
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf
open_access.oa_status	bronze
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10134
primary_topic.field.id	https://openalex.org/fields/13
primary_topic.field.display_name	Biochemistry, Genetics and Molecular Biology
primary_topic.score	0.9988999962806702
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1311
primary_topic.subfield.display_name	Genetics
primary_topic.display_name	Inflammatory Bowel Disease
related_works	https://openalex.org/W2582131160, https://openalex.org/W2488600916, https://openalex.org/W1995555245, https://openalex.org/W3194385729, https://openalex.org/W2999643437, https://openalex.org/W2790483177, https://openalex.org/W4255303081, https://openalex.org/W2802439938, https://openalex.org/W2048986416, https://openalex.org/W71416396
cited_by_count	5
counts_by_year[0].year	2024
counts_by_year[0].cited_by_count	1
counts_by_year[1].year	2019
counts_by_year[1].cited_by_count	4
locations_count	1
best_oa_location.id	doi:10.1093/ecco-jcc/jjy222.105
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S2735960814
best_oa_location.source.issn	1873-9946, 1876-4479
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	1873-9946
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Journal of Crohn s and Colitis
best_oa_location.source.host_organization	https://openalex.org/P4310311648
best_oa_location.source.host_organization_name	Oxford University Press
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310311648
best_oa_location.license
best_oa_location.pdf_url	https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Journal of Crohn's and Colitis
best_oa_location.landing_page_url	https://doi.org/10.1093/ecco-jcc/jjy222.105
primary_location.id	doi:10.1093/ecco-jcc/jjy222.105
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S2735960814
primary_location.source.issn	1873-9946, 1876-4479
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	1873-9946
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Journal of Crohn s and Colitis
primary_location.source.host_organization	https://openalex.org/P4310311648
primary_location.source.host_organization_name	Oxford University Press
primary_location.source.host_organization_lineage	https://openalex.org/P4310311648
primary_location.license
primary_location.pdf_url	https://academic.oup.com/ecco-jcc/article-pdf/13/Supplement_1/S073/27599190/jjy222.105.pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Journal of Crohn's and Colitis
primary_location.landing_page_url	https://doi.org/10.1093/ecco-jcc/jjy222.105
publication_date	2019-01-25
publication_year	2019
referenced_works_count	0
abstract_inverted_index.3	373
abstract_inverted_index.6	83, 188, 268
abstract_inverted_index.8	365, 409
abstract_inverted_index.<	202, 225, 250, 326
abstract_inverted_index.=	57
abstract_inverted_index.a	109, 120, 417
abstract_inverted_index.p	201, 224, 249
abstract_inverted_index.(p	325
abstract_inverted_index.1.	353
abstract_inverted_index.16	368
abstract_inverted_index.90	96
abstract_inverted_index.At	170
abstract_inverted_index.EH	167, 172, 322
abstract_inverted_index.HH	204, 309, 421
abstract_inverted_index.IV	93, 190, 384, 412
abstract_inverted_index.To	151
abstract_inverted_index.We	35
abstract_inverted_index.an	3
abstract_inverted_index.as	24, 119, 164, 432, 434
abstract_inverted_index.at	67, 79, 102, 279, 285, 290, 310, 363
abstract_inverted_index.in	27, 46, 54, 74, 89, 112, 175, 207, 232, 273, 336, 369, 426
abstract_inverted_index.is	2, 422
abstract_inverted_index.mg	97, 186, 266
abstract_inverted_index.of	17, 30, 39, 52, 115, 135, 140, 145, 179, 211, 236, 254, 292, 297, 315, 390, 401
abstract_inverted_index.on	41
abstract_inverted_index.or	137, 267, 277, 303, 312, 359
abstract_inverted_index.to	76, 91, 275
abstract_inverted_index.tx	195, 218, 243
abstract_inverted_index.10%	400
abstract_inverted_index.130	185, 265
abstract_inverted_index.95%	198, 221, 246
abstract_inverted_index.<1;	124
abstract_inverted_index.<5%	144
abstract_inverted_index.CI,	199, 222, 247
abstract_inverted_index.EH,	255, 391
abstract_inverted_index.HH,	256, 392
abstract_inverted_index.HH.	169
abstract_inverted_index.IV,	85, 305
abstract_inverted_index.IV.	270
abstract_inverted_index.PBO	276, 304
abstract_inverted_index.Ph3	49
abstract_inverted_index.SC;	98
abstract_inverted_index.Two	59
abstract_inverted_index.UC,	381
abstract_inverted_index.UC;	8
abstract_inverted_index.UST	40, 53, 82, 92, 95, 183, 212, 237, 264, 278, 284, 302, 385, 413
abstract_inverted_index.Wk8	80, 280, 311
abstract_inverted_index.and	14, 19, 43, 69, 86, 143, 155, 168, 177, 187, 209, 213, 234, 238, 257, 288, 295, 323, 328, 333, 342, 349, 366, 393, 428
abstract_inverted_index.are	33
abstract_inverted_index.did	404
abstract_inverted_index.for	6, 346, 356
abstract_inverted_index.had	387
abstract_inverted_index.not	73, 88, 272, 405
abstract_inverted_index.the	15, 28, 31, 37, 47, 113, 129, 370
abstract_inverted_index.tx)	317
abstract_inverted_index.was	117, 162, 173, 205, 230, 318
abstract_inverted_index.who	299, 403
abstract_inverted_index.(EH;	106
abstract_inverted_index.(HH)	127
abstract_inverted_index.(SC)	419
abstract_inverted_index.8.9%	235
abstract_inverted_index.HEMH	258, 324, 394, 415
abstract_inverted_index.Mayo	121, 337, 340, 343
abstract_inverted_index.PBO,	192
abstract_inverted_index.PBO.	398
abstract_inverted_index.UC(n	56
abstract_inverted_index.Week	364, 367
abstract_inverted_index.Wk16	313
abstract_inverted_index.Wk8,	171
abstract_inverted_index.Wk8.	71
abstract_inverted_index.also	107
abstract_inverted_index.both	153, 166, 330
abstract_inverted_index.data	10
abstract_inverted_index.from	64
abstract_inverted_index.than	395
abstract_inverted_index.that	286
abstract_inverted_index.time	287
abstract_inverted_index.well	433
abstract_inverted_index.were	62, 100, 259, 281
abstract_inverted_index.with	147, 182, 263, 283, 321, 329, 358, 378, 424
abstract_inverted_index.(PBO)	78
abstract_inverted_index.(UST)	1
abstract_inverted_index.(also	22
abstract_inverted_index.12.1%	294
abstract_inverted_index.13.8%	178
abstract_inverted_index.16.5%	296
abstract_inverted_index.19.3%	233
abstract_inverted_index.21.9%	210
abstract_inverted_index.26.6%	176
abstract_inverted_index.36.8%	208
abstract_inverted_index.961).	58
abstract_inverted_index.Among	376
abstract_inverted_index.HEMH.	308
abstract_inverted_index.Phase	372
abstract_inverted_index.Table	352
abstract_inverted_index.UNIFI	48, 371
abstract_inverted_index.Wk16.	103
abstract_inverted_index.Wk16;	291
abstract_inverted_index.after	411
abstract_inverted_index.colon	66
abstract_inverted_index.crypt	141
abstract_inverted_index.dose.	420
abstract_inverted_index.mg/kg	84, 189, 269
abstract_inverted_index.rates	253, 389
abstract_inverted_index.score	123
abstract_inverted_index.stool	347
abstract_inverted_index.study	51, 375
abstract_inverted_index.those	87, 382, 396
abstract_inverted_index.weeks	410
abstract_inverted_index.(HEMH)	161, 229
abstract_inverted_index.0.001)	327
abstract_inverted_index.12.5%;	245
abstract_inverted_index.12.8%;	197
abstract_inverted_index.15.0%;	220
abstract_inverted_index.Geboes	131
abstract_inverted_index.active	380
abstract_inverted_index.crypts	146
abstract_inverted_index.distal	65
abstract_inverted_index.higher	388
abstract_inverted_index.levels	332
abstract_inverted_index.macro-	154
abstract_inverted_index.rectal	350
abstract_inverted_index.score,	338, 341
abstract_inverted_index.second	418
abstract_inverted_index.these,	293
abstract_inverted_index.0.001).	203, 226, 251
abstract_inverted_index.Similar	252
abstract_inverted_index.absence	134, 139
abstract_inverted_index.achieve	406
abstract_inverted_index.changes	335
abstract_inverted_index.colonic	60
abstract_inverted_index.defined	118, 163
abstract_inverted_index.disease	430
abstract_inverted_index.effects	38
abstract_inverted_index.erosion	136
abstract_inverted_index.healing	13, 21, 105, 126, 160, 362
abstract_inverted_index.mucosa)	32, 116
abstract_inverted_index.mucosal	159, 228
abstract_inverted_index.partial	339
abstract_inverted_index.placebo	77
abstract_inverted_index.post-tx	334
abstract_inverted_index.scales,	157
abstract_inverted_index.symptom	344
abstract_inverted_index.therapy	5
abstract_inverted_index.treated	181, 282
abstract_inverted_index.without	360
abstract_inverted_index.Clinical	354
abstract_inverted_index.Subjects	72, 271
abstract_inverted_index.absolute	331
abstract_inverted_index.achieved	174, 206, 231, 260, 307, 414
abstract_inverted_index.activity	45, 431
abstract_inverted_index.biopsies	61, 99
abstract_inverted_index.clinical	407, 427
abstract_inverted_index.however,	9
abstract_inverted_index.obtained	101
abstract_inverted_index.outcomes	355
abstract_inverted_index.received	81, 94, 301
abstract_inverted_index.response	75, 90, 274, 408
abstract_inverted_index.subjects	180, 298, 357, 377, 402
abstract_inverted_index.unknown.	34
abstract_inverted_index.(adjusted	194, 217, 242
abstract_inverted_index.(combined	184
abstract_inverted_index.achieving	165
abstract_inverted_index.bleeding.	351
abstract_inverted_index.collected	63
abstract_inverted_index.comprised	128
abstract_inverted_index.criteria:	133
abstract_inverted_index.described	23, 108
abstract_inverted_index.doses)and	191
abstract_inverted_index.effective	4
abstract_inverted_index.encompass	152
abstract_inverted_index.endoscopy	122
abstract_inverted_index.evaluated	36
abstract_inverted_index.following	130, 261, 416
abstract_inverted_index.frequency	348
abstract_inverted_index.induction	50, 70, 262, 316, 374, 386
abstract_inverted_index.initially	300
abstract_inverted_index.receiving	383, 397
abstract_inverted_index.regarding	11
abstract_inverted_index.screening	68
abstract_inverted_index.subjects,	215, 240
abstract_inverted_index.symptoms.	436
abstract_inverted_index.Endoscopic	104
abstract_inverted_index.appearance	29, 114
abstract_inverted_index.associated	320, 423
abstract_inverted_index.endoscopic	20, 25, 44, 110, 429
abstract_inverted_index.epithelial	148
abstract_inverted_index.neutrophil	149
abstract_inverted_index.reductions	425
abstract_inverted_index.sub-scores	345
abstract_inverted_index.6.2–14.8;	248
abstract_inverted_index.7.9–17.8;	200
abstract_inverted_index.9.0–21.0;	223
abstract_inverted_index.PBO-treated	214, 239
abstract_inverted_index.Ustekinumab	0
abstract_inverted_index.combination	16
abstract_inverted_index.difference,	196, 219, 244
abstract_inverted_index.improvement	26, 111
abstract_inverted_index.microscopic	156
abstract_inverted_index.score-based	132
abstract_inverted_index.ulceration,	138
abstract_inverted_index.destruction,	142
abstract_inverted_index.histological	12, 18, 42, 125, 361
abstract_inverted_index.re-evaluated	289
abstract_inverted_index.respectively	193, 216, 241
abstract_inverted_index.(irrespective	314
abstract_inverted_index.Approximately	399
abstract_inverted_index.infiltration.	150
abstract_inverted_index.respectively,	306
abstract_inverted_index.significantly	319
abstract_inverted_index.Histo-endoscopic	227
abstract_inverted_index.histo-endoscopic	158
abstract_inverted_index.patient-reported	435
abstract_inverted_index.moderate–severe	7, 55
abstract_inverted_index.moderately–severely	379
cited_by_percentile_year.max	98
cited_by_percentile_year.min	90
countries_distinct_count	4
institutions_distinct_count	8
sustainable_development_goals[0].id	https://metadata.un.org/sdg/2
sustainable_development_goals[0].score	0.6299999952316284
sustainable_development_goals[0].display_name	Zero hunger
citation_normalized_percentile.value	0.74153097
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False